Advanced search×

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

Jian-Mei Hou, Alastair Greystoke, Lee Lancashire, Jeff Cummings, Tim Ward, Ruth Board, Eitan Amir, Sarah Hughes, Matthew Krebs, Andrew Hughes, Malcolm Ranson, Paul Lorigan, Caroline Dive, and Fiona H Blackhall

Am J Pathol 175(2):9 (2009) PMID 19628770

Serological cell death biomarkers and circulating tumor cells (CTCs) have potential uses as tools for pharmacodynamic blood-based assays and their subsequent application to early clinical trials. In this study, we evaluated both the expression and clinical significance of CTCs and serological cell death biomarkers in patients with small cell lung cancer. Blood samples from 88 patients were assayed using enzyme-linked immunosorbent assays for various cytokeratin 18 products (eg, M65, cell death, M30, and apoptosis) as well as nucleosomal DNA. CTCs (per 7.5 ml of blood) were quantified using Veridex CellSearch technology. Before therapeutic treatment, cell death biomarkers were elevated in patients compared with controls. CTCs were detected in 86% of patients; additionally, CD56 was detectable in CTCs, confirming their neoplastic origin. M30 levels correlated with the percentage of apoptotic CTCs. M30, M65, lactate dehydrogenase, and CTC number were prognostic for patient survival as determined by univariate analysis. Using multivariate analysis, both lactate dehydrogenase and M65 levels remained significant. CTC number fell following chemotherapy, whereas levels of serological cell death biomarkers peaked at 48 hours and fell by day 22, mirroring the tumor response. A 48-hour rise in nucleosomal DNA and M30 levels was associated with early response and severe toxicity, respectively. Our results provide a rationale to include the use of serological biomarkers and CTCs in early clinical trials of new agents for small cell lung cancer.

Copyright © 2009 Elsevier Ltd. All rights reserved.

DOI: 10.2353/ajpath.2009.090078
Version: za2963e q8za5 q8zb8 q8zc2 q8zdc q8ze1 q8zf1 q8zg3

Similar articles you may find interesting…

  1. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
    Adam Dangoor, Paul Lorigan, ... Robert Hawkins

    Cancer Immunol Immunother 59(6):863-73 (2010) PMID 20043222

    DNA.Mel3 and MVA.Mel3 in a prime-boost protocol generated high rates of immune response to melanoma antigen epitopes. The treatment was well tolerated and the correlation of immune responses with patient outcomes encourages further investigation....
  2. Fit-for-purpose biomarker method validation in anticancer drug development
    Jeffrey Cummings, Tim H Ward, and Caroline Dive

    Drug Discov Today 15(19-20):10 (2010) PMID 20708097

    The introduction of new anticancer drugs into the clinic is often hampered by a lack of qualified biomarkers. Method validation is indispensable to successful biomarker qualification and is also a regulatory requirement. Recently, the fit-for-purpose approach has been developed to pr...
  3. Lung cancer after treatment for breast cancer
    Paul Lorigan, Raffaele Califano, ... Nick Thatcher

    Lancet Oncol 11(12):9 (2010) PMID 20541465

    We review data on the effect of treatment factors (ie, surgery type, radiotherapy technique, and adjuvant chemotherapy) and patient factors (ie, age and smoking) on the risk of developing a subsequent lung cancer. The evidence suggests that older radiotherapy techniques were associated with a substa...